title,time_published,url,ticker,relevance_score,ticker_sentiment_label,ticker_sentiment_score
Bio-Path Holdings Outlines Rationale for Development of BP1001-A as Potential Treatment for Obesity in Type 2 Diabetes Patients,20241211T120000,https://www.globenewswire.com/news-release/2024/12/11/2995241/0/en/Bio-Path-Holdings-Outlines-Rationale-for-Development-of-BP1001-A-as-Potential-Treatment-for-Obesity-in-Type-2-Diabetes-Patients.html,LRHC,0.023124,Neutral,-0.137518
